Levetiracetam Ucb

Levetiracetam, the active ingredient in Levetiracetam Ucb, is an anticonvulsant presented as an intravenous formulation for intravenous use. It is employed as adjunctive therapy for partial‑onset seizures and generalized tonic‑clonic seizures in patients with epilepsy.

GNH USA supplies Levetiracetam Ucb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic drug that acts on seizure pathways to reduce abnormal neuronal firing.

Partial‑onset seizures: adjunctive therapy that lowers seizure frequency in patients with focal epilepsy. Generalized tonic‑clonic seizures: adjunctive therapy that helps achieve better seizure control in patients with primary generalized epilepsy. Epilepsy (broad): incorporated into overall seizure management strategies as part of combination therapy.

Levetiracetam may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness. - Fatigue or somnolence. - Headache. - Nausea or gastrointestinal discomfort. - Irritability or mood changes. - Nasal congestion or upper respiratory symptoms.

Serious or Rare Side Effects: - Severe allergic reactions, including anaphylaxis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts or behavior. - Severe skin rash or hypersensitivity. - Blood dyscrasias such as neutropenia or thrombocytopenia. - Hepatic dysfunction or elevated liver enzymes.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for potential risks.

Renal function: adjust dosing in patients with impaired renal clearance. Psychiatric symptoms: monitor for mood changes, depression, or suicidal ideation. Drug discontinuation: avoid abrupt cessation to prevent seizure exacerbation. Pregnancy: risk category unknown; weigh benefits against potential fetal risks. Drug interactions: review concomitant medications for possible pharmacokinetic effects. Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Levetiracetam can interact with several medications, influencing its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine or phenytoin: may reduce levetiracetam plasma concentrations. - Enzyme‑inducing antiepileptics (e.g., phenobarbital): can lower drug exposure. - Concomitant use with other SV2A ligands: may increase risk of CNS depression.

Moderate Interactions (Monitor Closely): - Sedative agents (e.g., benzodiazepines, opioids): may enhance drowsiness. - Hormonal contraceptives: potential reduction in contraceptive effectiveness; advise alternative methods.